Additionally, an ongoing phase II trial is evaluating sapanisertib, a dual mTORC1/2 inhibitor, in patients with relapsed or refractory NRF2-mutant NSCLC (NCT05275673). The gene discussed is NFE2L2; the disease is non-small cell lung carcinoma.